Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 21, 2014; 20(31): 10960-10968
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10960
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10960
Figure 1 Time to progression in the chemotherapeutic agent irinotecan, gemcitabine and doxorubicin groups.
A: There was a significant difference in time to progression among the three groups (P = 0.018). B: Time to progression in intermediate-stage HCC among the three groups (P = 0.373). HCC: Hepatocellular carcinoma; CPT-11: Chemotherapeutic agent irinotecan; GEM: Gemcitabine; BCLC: Barcelona Clinic Liver Cancer Group.
- Citation: Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968
- URL: https://www.wjgnet.com/1007-9327/full/v20/i31/10960.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i31.10960